Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
CANTATA: primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839)+ cabozantinib versus Pbo+ cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies
Therefore, this drug class offers benefits for obesity in patients with type 2 diabetes, a common comorbidity
Diet-induced obesity attenuates cytokine production following an immune challenge
Any research information provided is for informational purposes only.
US$ 26.84
US$ 23.92
US$ 28.92
US$ 22.23
US$ 28.95
US$ 23.67
US$ 29.52
US$ 20.80
US$ 20.59
US$ 23.28
US$ 24.83
